CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop selective inhibitors targeting liver receptor homologue 1, a protein involved in breast cancer growth. By blocking its interaction with coactivator proteins, the research seeks to counteract resistance to existing breast cancer therapies.
Breast cancer is the most common cancer in women in the western world, and 80% of breast cancers express the estrogen receptor (ER).
Whilst inhibitors of ER action such as Tamoxifen and inhibitors of estrogen biosynthesis (e.g. aromatase inhibitors such as Anastrozole) have contributed to reductions in breast cancer mortality, resistance to these agents is a major problem.
Such resistance could potentially be minimised by switching therapy with endocrine agents and as such there is an urgent cli…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
